PMID- 37973893
OWN - NLM
STAT- MEDLINE
DCOM- 20240211
LR  - 20240304
IS  - 1476-5365 (Electronic)
IS  - 0268-3369 (Linking)
VI  - 59
IP  - 2
DP  - 2024 Feb
TI  - Efficacy of CD19 directed therapies in patients with relapsed or refractory large 
      b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell 
      therapy.
PG  - 211-216
LID - 10.1038/s41409-023-02148-4 [doi]
AB  - Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell 
      lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two 
      CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and 
      loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these 
      CD19 directed therapies in patients who relapse after CD19 directed CAR-T 
      (CD19-CART) therapy is not well understood. We conducted a multi-center study of 
      patients with R/R LBCL that received either tafa-len or loncaT at any timepoint 
      for R/R disease after CD19-CART therapy. Fifty-three patients were included in 
      this study with the median follow up of 56 (9.1-199) weeks from CAR-T infusion. 
      Median number of systemic therapies pre-CAR-T therapy was 3 (range: 1-6); 
      axicabtagene ciloleucel was the most utilized CAR-T product (n = 32,60%). Median 
      time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2-38.2) months with 
      median number of lines of therapy between CAR-T therapy and these regimens of 1 
      (0-5). Combined overall response rate and complete response rates were 27% and 
      10%, respectively. Median duration of response was 13.3 (2.1-56.7) weeks. In this 
      real-world study, the use of currently approved CD19-directed therapies to treat 
      R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration 
      of responses.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Limited.
FAU - Iqbal, Madiha
AU  - Iqbal M
AUID- ORCID: 0000-0001-6752-5440
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. 
      Iqbal.Madiha@Mayo.Edu.
FAU - Jagadeesh, Deepa
AU  - Jagadeesh D
AD  - Cleveland Clinic, Cleveland, OH, USA.
FAU - Chavez, Julio
AU  - Chavez J
AD  - Moffitt Cancer Center, Tampa, FL, USA.
FAU - Khurana, Arushi
AU  - Khurana A
AD  - Division of Hematology, Mayo Clinic, Rochester, MN, USA.
FAU - Rosenthal, Allison
AU  - Rosenthal A
AD  - Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
FAU - Craver, Emily
AU  - Craver E
AUID- ORCID: 0000-0003-0334-9606
AD  - Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
FAU - Epperla, Narendranath
AU  - Epperla N
AUID- ORCID: 0000-0002-8216-3457
AD  - Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, The Ohio 
      State University, Columbus, OH, USA.
FAU - Li, Zhuo
AU  - Li Z
AD  - Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
FAU - Isufi, Iris
AU  - Isufi I
AD  - Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA.
FAU - Awan, Farrukh T
AU  - Awan FT
AD  - Harold C. Simmons Comprehensive Cancer Center and University of Texas 
      Southwestern Medical Center, Dallas, TX, USA.
FAU - Dholaria, Bhagirathbhai R
AU  - Dholaria BR
AUID- ORCID: 0000-0003-2371-3655
AD  - Vanderbilt- Ingram Cancer Center and Vanderbilt University Medical center, 
      Nashville, TN, USA.
FAU - Maakaron, Joseph E
AU  - Maakaron JE
AUID- ORCID: 0000-0002-1732-6694
AD  - Division of Hematology, Oncology and Transplantation, University of Minnesota, 
      Minneapolis, MN, USA.
FAU - Sandoval-Sus, Jose D
AU  - Sandoval-Sus JD
AD  - Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL, USA.
FAU - Mishra, Rahul
AU  - Mishra R
AD  - Cleveland Clinic, Cleveland, OH, USA.
FAU - Saha, Aditi
AU  - Saha A
AUID- ORCID: 0000-0003-3421-3971
AD  - Moffitt Cancer Center, Tampa, FL, USA.
FAU - Annunzio, Kaitlin
AU  - Annunzio K
AD  - Arthur G. James Cancer Hospital & Richard J. Solove Research Institute, The Ohio 
      State University, Columbus, OH, USA.
FAU - Bhaskar, Shakthi T
AU  - Bhaskar ST
AD  - Vanderbilt- Ingram Cancer Center and Vanderbilt University Medical center, 
      Nashville, TN, USA.
FAU - Sumransub, Nuttavut
AU  - Sumransub N
AUID- ORCID: 0000-0001-7456-0623
AD  - Division of Hematology, Oncology and Transplantation, University of Minnesota, 
      Minneapolis, MN, USA.
FAU - Fijalka, Andrew
AU  - Fijalka A
AD  - Department of Pharmacy-M Health Fairview University of Minnesota Medical Center, 
      Minneapolis, MN, USA.
FAU - Ivanov, Stanislav A
AU  - Ivanov SA
AD  - Moffitt Cancer Center at Memorial Healthcare System, Pembroke Pines, FL, USA.
FAU - Lin, Yi
AU  - Lin Y
AUID- ORCID: 0000-0002-1556-6416
AD  - Division of Hematology, Mayo Clinic, Rochester, MN, USA.
FAU - Kharfan-Dabaja, Mohamed A
AU  - Kharfan-Dabaja MA
AUID- ORCID: 0000-0001-7394-5185
AD  - Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20231116
PL  - England
TA  - Bone Marrow Transplant
JT  - Bone marrow transplantation
JID - 8702459
RN  - 0 (Antigens, CD19)
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - Humans
MH  - Antigens, CD19
MH  - Cell- and Tissue-Based Therapy
MH  - Immunotherapy, Adoptive
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy/pathology
MH  - Neoplasm Recurrence, Local/drug therapy
MH  - *Receptors, Chimeric Antigen/therapeutic use
EDAT- 2023/11/17 15:30
MHDA- 2024/02/09 06:43
CRDT- 2023/11/17 00:30
PHST- 2023/08/09 00:00 [received]
PHST- 2023/11/03 00:00 [accepted]
PHST- 2023/10/18 00:00 [revised]
PHST- 2024/02/09 06:43 [medline]
PHST- 2023/11/17 15:30 [pubmed]
PHST- 2023/11/17 00:30 [entrez]
AID - 10.1038/s41409-023-02148-4 [pii]
AID - 10.1038/s41409-023-02148-4 [doi]
PST - ppublish
SO  - Bone Marrow Transplant. 2024 Feb;59(2):211-216. doi: 10.1038/s41409-023-02148-4. 
      Epub 2023 Nov 16.